CareDx Earnings Calls

Q1 2025 Beat
$0.0900 (50.00%)
Release date Apr 30, 2025
EPS estimate $0.0600
EPS actual $0.0900
EPS Surprise 50.00%
Revenue estimate 84.535M
Revenue actual 84.685M
Revenue Surprise 0.177%
Q4 2024 Beat
$0.180 (260.00%)
Release date Feb 26, 2025
EPS estimate $0.0500
EPS actual $0.180
EPS Surprise 260.00%
Revenue estimate 84.558M
Revenue actual 86.579M
Revenue Surprise 2.39%
Q3 2024 Beat
$0.140 (1,300.00%)
Release date Nov 04, 2024
EPS estimate $0.0100
EPS actual $0.140
EPS Surprise 1,300.00%
Revenue estimate 82.164M
Revenue actual 82.883M
Revenue Surprise 0.88%
Q2 2024 Beat
$0.250 (292.31%)
Release date Jul 31, 2024
EPS estimate -$0.130
EPS actual $0.250
EPS Surprise 292.31%
Revenue estimate 79.55M
Revenue actual 92.274M
Revenue Surprise 15.99%

Last 4 Quarters for CareDx

Below you can see how CDNA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q2 2024 Beat
Release date Jul 31, 2024
Fiscal end date Jun 30, 2024
Price on release $19.99
EPS estimate -$0.130
EPS actual $0.250
EPS surprise 292.31%
Date Price
Jul 25, 2024 $18.87
Jul 26, 2024 $19.01
Jul 29, 2024 $18.72
Jul 30, 2024 $18.76
Jul 31, 2024 $19.99
Aug 01, 2024 $23.58
Aug 02, 2024 $22.88
Aug 05, 2024 $23.69
Aug 06, 2024 $25.01
4 days before 5.94%
4 days after 25.11%
On release day 17.96%
Change in period 32.54%
Q3 2024 Beat
Release date Nov 04, 2024
Fiscal end date Sep 30, 2024
Price on release $22.93
EPS estimate $0.0100
EPS actual $0.140
EPS surprise 1,300.00%
Date Price
Oct 29, 2024 $22.60
Oct 30, 2024 $22.98
Oct 31, 2024 $22.13
Nov 01, 2024 $22.64
Nov 04, 2024 $22.93
Nov 05, 2024 $22.90
Nov 06, 2024 $23.21
Nov 07, 2024 $23.88
Nov 08, 2024 $23.65
4 days before 1.46%
4 days after 3.14%
On release day -0.131%
Change in period 4.65%
Q4 2024 Beat
Release date Feb 26, 2025
Fiscal end date Dec 31, 2024
Price on release $21.10
EPS estimate $0.0500
EPS actual $0.180
EPS surprise 260.00%
Date Price
Feb 20, 2025 $23.38
Feb 21, 2025 $22.29
Feb 24, 2025 $21.37
Feb 25, 2025 $20.89
Feb 26, 2025 $21.10
Feb 27, 2025 $21.06
Feb 28, 2025 $22.15
Mar 03, 2025 $21.13
Mar 04, 2025 $20.30
4 days before -9.75%
4 days after -3.79%
On release day -0.190%
Change in period -13.17%
Q1 2025 Beat
Release date Apr 30, 2025
Fiscal end date Mar 31, 2025
Price on release $16.88
EPS estimate $0.0600
EPS actual $0.0900
EPS surprise 50.00%
Date Price
Apr 24, 2025 $18.49
Apr 25, 2025 $18.48
Apr 28, 2025 $18.25
Apr 29, 2025 $18.13
Apr 30, 2025 $16.88
May 01, 2025 $15.07
May 02, 2025 $15.00
May 05, 2025 $15.17
May 06, 2025 $14.18
4 days before -8.71%
4 days after -16.00%
On release day -10.72%
Change in period -23.31%

CareDx Earnings Call Transcript Summary of Q1 2025

Here’s a summary of key points from CareDx’s First Quarter 2025 Earnings Conference Call that investors should be aware of:

Financial Performance

  • Quarterly Revenue: CareDx reported revenue of $84.7 million for Q1 2025, an 18% increase year-over-year.
  • Testing Services Revenue: Revenue from Testing Services was $61.9 million, up 15% year-over-year, with a volume of approximately 47,100 tests, a 12% increase from the previous year.
  • Adjusted EBITDA: The company achieved an adjusted EBITDA of $4.6 million, significantly improving from an adjusted EBITDA loss of $1.9 million in Q1 2024.
  • Cash Position: CareDx ended the quarter with $231 million in cash and equivalents, with no debt.
  • Guidance for 2025: The company reiterated its revenue guidance of $365 million to $375 million, with an adjusted EBITDA gain of $29 million to $33 million.

Growth Strategies and Product Development

  • Market Expansion: CareDx is seeing growth across all organ testing areas (heart, kidney, lung) and recorded its seventh consecutive quarter of sequential testing volume growth.
  • New Product Launches: Two expanded indications for AlloSure were launched: one for pediatric heart transplant patients and the other for simultaneous pancreas-kidney transplant patients. These are expected to significantly broaden the addressable market.
  • Payer Coverage: The company is making strides in expanding payer coverage, having added 15.5 million covered lives for AlloSure testing and finalized a new CPT code for AlloSure that is expected to improve in-network coverage.

Clinical Evidence and Innovation

  • Significant data was presented at the International Society for Heart and Lung Transplantation (ISHLT) conference, supporting the effectiveness of CareDx’s testing solutions.
  • Notable research underscored that AlloMap Heart and AlloSure may provide better patient outcome predictions compared to traditional biopsy methods.

Operational Excellence and Cost Management

  • CareDx is focused on operational excellence, aiming to improve processes that enhance scale without increasing operating expenses disproportionately.
  • The company has successfully minimized G&A expenses and aims to reduce stock-based compensation by 35% to 40% in 2025.

Market Insights and Future Projections

  • Surveillance testing volumes are showing signs of returning, particularly in kidney transplant protocols.
  • The company aims to leverage new clinical data and payer contracts to drive higher average selling prices (ASPs).
  • CareDx is optimistic about the potential for increasing transplant volumes as they anticipate favorable conditions in the latter half of the year.

Risks and Considerations

  • As always, investors should be mindful of the risks associated with forward-looking statements, including uncertainties in the healthcare landscape, reimbursement rates, and operational challenges.

This summary outlines both the current performance and future strategies of CareDx, making it useful for investors looking to assess the company's market position and growth potential.

CareDx Earnings History

Earnings Calendar

FAQ

When is the earnings report for CDNA?
CareDx (CDNA) has scheduled its earnings report for Jul 30, 2025 after the markets close.

What is the CDNA price-to-earnings (P/E) ratio?
CDNA P/E ratio as of May 09, 2025 (TTM) is 13.87.

What is the CDNA EPS forecast?
The forecasted EPS (Earnings Per Share) for CareDx (CDNA) for the first fiscal quarter 2025 is $0.120.

What are CareDx's retained earnings?
On its balance sheet, CareDx reported retained earnings of $84.69 million for the latest quarter ending Mar 31, 2025.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT CAREDX
CareDx
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The co...
GOLDEN STAR
Ticker Change Signal Date
BAX
$30.72
0.586% May 07
HBM
$7.41
4.05% May 05
P
PENG
$17.23
2.21% May 05
A
AORT
$23.77
21.62% May 05
PODD
$257.01
20.88% May 02

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE